1853MO Efficacy and safety of rilvegostomig, an anti-PD-1/TIGIT bispecific antibody, for checkpoint inhibitor (CPI)-naïve metastatic non-small cell lung cancer (mNSCLC): ARTEMIDE-01

Byoung Chul Cho, J.T.J.N. Hiltermann, Hiroki Izumi, Mariana Brandão, S.C.S. Oliveira, Pongwut Danchaivijitr, Enriqueta Felip, Gwo Fuang Ho, K. Leventakos, Yongsheng Li, S. Sugawara, P-J. Voon, Els Wauters, T-Y. Yang, Tatsuya Yoshida, H. Chen, Ikbel Achour, Steve Colebrook, N. Liu, Yulei Wang